Search

Your search for "pcsa" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at Upcoming EF Hutton Global Conference

May 6, 2024

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, will be represented at this month’s EF Hutton Annual Global Conference. According to the announcement, key company officials will be attending the event, which will be held in New York City on May […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Dr. Steven Cha to Lead Clinical Development of Oncology Programs

April 30, 2024

Processa (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety. The company today announced that it has named Steven Cha, M.D. as senior vice president of clinical research. In the newly created position, Dr. Cha’s experience as an oncologist as well as in […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Presents New Data from NGC-Cap Phase 1b Trial at AACR Annual Meeting

April 11, 2024

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, participated at this year’s annual American Association for Cancer Research (“AACR”). According to the announcement, the company presented two abstracts at the conference, including new phase […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference

March 28, 2024

Processa (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today announced that its CEO George Ng will present a corporate update at the MedInvest Biotech and Pharma Investor Conference being held on April 3 […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at American Association for Cancer Research Annual Meeting

March 25, 2024

Processa (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today announced that it will have two posters at the American Association for Cancer Research Annual Meeting, which is taking place in San Diego from […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at 2024 BIO CEO & Investor Conference

February 21, 2024

Processa (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, today announced that its CEO George Ng will present a corporate update at the 2024 BIO CEO & Investor Conference. The event is slated to take place on […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate in Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference

February 15, 2024

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, will be represented at this month’s Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference. According to the announcement, Processa CEO George Ng will be presenting during the […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $7M Public Offering

February 2, 2024

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, has closed on its previously announced public offering. The offering, which closed on Jan. 30, 2024, was comprised of 1,555,555 shares of common stock (or prefunded […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Pricing Information for $7M Public Offering

January 26, 2024

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, is announcing the pricing of its public offering. The offering is comprised of 1,555,555 shares of common stock (or prefunded warrants in lieu thereof) and common […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Completes Phase 1b Safety Evaluation of NGC-Cap

January 25, 2024

Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer. The company today announced successful completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (“NGC-Cap”). Two dosage regimens were […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Plans to Expand NGC-Cap Program into Advanced or Metastatic Breast Cancer

January 19, 2024

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company developing the next generation of chemotherapeutic drugs, today announced plans to expand the development of Next Generation Capecitabine (“NGC-Cap”) into the treatment of advanced or metastatic breast cancer beginning with its next Phase 2 trial. NGC-Cap combines the administration of PCS6422, the company’s irreversible dihydropyrimidine dehydrogenase (“DPD”) […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces 1-for-20 Reverse Stock Split

January 18, 2024

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, has announced a 1-for-20 reverse stock split. The reverse split was initially approved by shareholders in November 2023, and on Jan. 8, 2024, the company’s board of […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Biotech Showcase 2024

January 3, 2024

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be featured at this month’s Biotech Showcase 2024. The premier event is slated for Jan. 8–10, 2024, in San Francisco. During the event, Processa CEO George […]

InvestorNewsBreaks

InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Sees New Sales in Rapidly Growing Spaces, Including Healthcare and Higher Education

December 19, 2023

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, is continuing to see consistent upward momentum in sales. Most recently the company announced two new contracts — one in healthcare and one in higher education, which are both rapidly growing spaces for Knightscope. According to the company, […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Provides Interim Analysis from Phase 1b NGC-Cap Trial

December 19, 2023

Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the safety and efficacy for more cancer patients. Today the company provided an interim analysis from its phase 1b study of its Next Generation Capecitabine (“NGC-Cap”). “These initial data provide our first confirmatory clinical evidence […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Gains Helpful Guidance on Overall Design of NGC-Cap Phase 2 Study

December 13, 2023

Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer. The company today announced the outcomes from a successful meeting with the U.S. Food and Drug Administration (“FDA”) regarding Processa’s next Phase 2 study supporting […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in December MedInvest Oncology Investor Conference

November 30, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be presenting at the MedInvest Oncology Investor Conference. According to the announcement, Dr. David Young, president of research and development for Processa, will be presenting virtually during […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Shareholder Letter

November 29, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, has released a shareholder letter from CEO Georg Ng. In the letter, Ng notes that because he was recently appointed CEO, he wanted investors to get a […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Unexpected Passing of Board Member

November 14, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announced that Virgil Thompson passed away unexpectedly on Nov. 9, 2023. Thompson, 83 years old, had served on PCSA’s board of directors since the company was formed […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming Orphan Drugs and Rare Diseases Global Congress

November 9, 2023

Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today announced that its president of research and development, Dr. David Young, will present at the 20th Orphan Drugs and Rare Diseases Global Congress […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Creates Advisory Board, Names Renowned Experts as Members

November 1, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, has created a world-class oncology advisory board. The board will include key opinion leaders from several nationally recognized institutions. Board members include Philip A. Philip, MD, PhD, […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at Upcoming ThinkEquity Conference

October 13, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be presenting at this month’s ThinkEquity Conference. The conference is scheduled for Oct. 19, 2023, and will be held in New York City. During the […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming H.C. Wainwright Global Investment Conference

September 6, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be presenting at the 25th annual H.C. Wainwright Global Investment Conference. The conference is slated for Sept. 11–13, 2023, and will be held in New […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Encouraging Results on Potential Cancer Treatment Approach

August 17, 2023

Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today provided an interim analysis from its ongoing phase 1B trial of Next Generation Capecitabine (“NGC-Cap”) in patients with gastrointestinal cancer, which identifies a […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming Sidoti & Co. Micro Cap Virtual Conference

August 11, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be presenting at this month’s Sidoti & Co. Micro Cap Virtual Conference. The two-day event is scheduled for Aug. 16–17, 2023. According to the announcement, […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces New Stage of Corporate Leadership

August 8, 2023

Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today announced its appointment of industry veteran George Ng to serve as its chief executive officer and as a board director as of Aug. […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at MedInvest Oncology Conference

June 15, 2023

Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company has announced that its CEO David Young, Pharm.D., Ph.D. will present at the MedInvest Oncology Investor Conference taking place on June 21-22, 2023, […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Conduct NGC-Cap Trial Based on FDA Guidance and Project Optimus Oncology Initiative

May 18, 2023

Processa Pharmaceuticals (NASDAQ: PCSA) today announced its receipt of guidance from the U.S. Food and Drug Administration (“FDA”) regarding the company’s next trial for Next Generation Chemotherapy-Capecitabine (“NGC-Cap”). The phase 2 safety-efficacy trial will study a combination of PCS6422 and capecitabine for colorectal cancer patients following the principles of FDA’s Project Optimus Oncology Initiative, the […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Report on Gastroparesis Results at Annual Digestive Disease Meeting

April 28, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be presenting at the annual Digestive Disease Week (“DDW”) conference. The conference will be held on May 6–9, 2023, in Chicago. The company will be […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases FY 2022 Financials, Corporate Update

March 31, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a developer of next-generation chemotherapy drugs that provide a better safety-efficacy profile than widely used FDA-approved counterparts, is reporting on its full-year 2022 financial results and has also noted key accomplishments for the year. According to the announcement, PCSA will be focusing on the development of its next-generation chemotherapy drugs this […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Schedules Conference Call/Webinar to Review FY 2022 Results, Discuss Corporate Updates

March 23, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a developer of next-generation chemotherapy drugs that provide a better safety-efficacy profile than widely used FDA-approved counterparts, is hosting a conference call to discuss 2022 year-end results and company updates. The call, which will also be available through a live webcast, is slated to begin at 4:30 p.m. EST on March […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Doses First Patient in Key Study of Next-Generation Chemotherapy-Capecitabine

March 17, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a developer of next-generation chemotherapies (“NGCs”), has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group. This group is designed to obtain critical information on the drug exposure vs. adverse event relationship. The company noted that patients treated with next-generation chemotherapy-capecitabine have not had hand-foot syndrome or cardiotoxicity adverse events. “We […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Oppenheimer Healthcare Conference

March 7, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), the developer of the next-generation chemotherapy drugs that will provide a better safety-efficacy profile than widely used FDA-approved counterparts, will be presenting at the 33rd annual Oppenheimer Healthcare Conference, held on March 14, 2023. According to the announcement, Processa Pharmaceuticals CEO and president Dr. David Young is scheduled for a virtual […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Prioritizes Development of Next Generation Chemotherapies

February 21, 2023

Processa Pharmaceuticals (NASDAQ: PCSA) today reiterates the strategic prioritization of its pipeline of proprietary oncology drugs, defined as Next Generation Chemotherapies (“NGCs”). According to the update, previous studies with these NGCs suggest potential improvement in the safety-efficacy profile, significantly differentiating these NGCs from their three presently widely used counterparts – capecitabine, gemcitabine and irinotecan. “The […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $6.25M Registered Direct Offering

February 15, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing next-generation chemotherapy drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient’s survival and/or quality of life, announced that it has closed on its registered direct offering. The company noted that the $6.25 million offering included definitive agreements with […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces $6.25M Registered Direct Offering

February 10, 2023

Processa Pharmaceuticals (NASDAQ: PCSA) is a diversified clinical-stage company developing next generation chemotherapy drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient’s survival and/or quality of life. The company today announced its entry into definitive agreements with retail investors for the purchase and sale of 7,812,544 common […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Biotech Showcase

January 4, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients with unmet medical need conditions, today announced that its CEO Dr. David Young will present an update on Processa’s future therapeutic focus and strategy at the upcoming Biotech Showcase. The presentation is scheduled to begin […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) PCS12852 Demonstrates Clinically Meaningful Improvements in Gastroparesis Symptoms

December 14, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients with unmet medical need conditions, today announced positive top-line results on the clinical symptoms associated with gastroparesis from a 4-week Phase 2A study of PCS12852. The randomized, dose-response study for the treatment of patients with […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) PCS12852 Demonstrates Improved Gastric Emptying in Phase 2A Trial

November 8, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, today announced positive results from its PCS12852 Phase 2A trial in patients with moderate to severe gastroparesis. The four-week placebo-controlled, randomized, dose-response trial was designed to evaluate the […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q3 2022 Results, Provide Pipeline Update

November 2, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical need conditions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Nov. 8, 2022, to discuss its third quarter 2022 results and provide an […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).